The top 50 specialty companies profiled in this report generated about $88.46 billion in combined 2010 healthcare revenue, representing nearly a 10% increase compared to their 2009 total. The leading 50 specialty players spent 9% more on healthcare R&D in 2010 than they did during the previous calendar term.
This report focusing on the Top 50 Specialty Companies features a compilation of generic, drug-delivery, drug-development, niche pharmaceutical, and other specialty healthcare players.
The report ranks the top 50 specialty companies that are publicly traded by 2010 revenue. The charts for the specialty companies encompass total revenue, R&D expenditure, net income, earnings per share, total assets, and shareholders' equity for 2010 and 2009, as well as headquarters location, Website and the main areas of business concentration.
Profiles on each company include a business overview, select 2011 news, quick facts and key products, and most-recent quarterly financial results.
Additionally provided are chart breakdowns of revenue and the number of companies for the specialty pharmaceutical, generic, and drug-delivery sectors.